Community-onset extended-spectrum β-lactamase producing Escherichia coli in urinary tract infections in children from 2015 to 2016

Prevalence, risk factors, and resistances

Iñigo Pérez Heras, MD1, Juan Carlos Sanchez-Gomez, MD, Pedro Beneyto-Martin, MD, Laura Ruano-de-Pablo, MD, Begoña Losada-Pinedo, MD

Abstract

Over the past 10 years, the resistances among microbes are increasing gradually in Europe and greater resistances are seen in southern countries. We studied the prevalence of community-onset ESBL-producing Escherichia coli urinary tract infections in children.

As secondary objectives, we analyzed associated risk factors and the resistance patterns in ESBL-producing E coli isolates. Retrospective observational study in a tertiary care hospital about children ≤14 years old with community-onset E coli urinary tract infection. The variables studied were age, sex, ESBL-producing, antibiotic therapy 7 to 30 days before the infection, hospitalization 7 to 30 days before the infection, nephrourological pathology, and vesicoureteral reflux.

Between January 1st, 2015 and December 31st, 2016, 229 isolates of E coli were obtained, of whom 21 (9.2%) where ESBL-producing E. coli. Median age in non-ESBL-producing was 18 months versus 7 months in ESBL-producing group. Fourteen (66%) of the ESBL-producing group were men (P = .001), 5 (23.8%) were hospitalized 30 days before the infection (P = .001), 12 (57.1%) had nephrourological pathology (P = .003), 6 (28.5%) had vesicoureteral reflux (P = .02). Previous antibiotic therapy was not statistically significant. Multiple regression analyses between sex and 30 days previous hospitalization were P = .51. Multidrug resistant isolates among ESBL-producing E col was 12 (57%). The retrospective study allowed assessing the problem of ESBL-producing isolates in the outpatient settings. Some risk factors from past studies were confirmed and a combined risk is suggested. The resistant spectrum should be taken into account when choosing antibiotic regimens.

Abbreviations: ESBL = extended-spectrum beta-lactamase, UTI = urinary tract infections.

Keywords: β-lactamases, community-acquired infections, Escherichia coli, spain/epidemiology, urinary tract infections

1. Introduction

Over the past 10 years, the resistances among microbes are increasing gradually in Europe. This is especially important in Spain, where all the studies and reports suggest that our rates of antibiotic resistance are greater than other countries. Most of the studies were made in adult population, or at least not specifically in children. This means that there is a gap of information that must be completed, in order to improve national health surveillance programs in our country.

On the other hand, the prevalence of urinary tract infections in children goes from 2% to 5%, with a risk of developing permanent renal damage in children below 2 years old.

Statistical data are quite different between countries. In the USA, reports show a prevalence of extended-spectrum β-lactamase (ESBL) producing Escherichia coli urinary tract infections (UTI) of 3%. In Mexico, the studies show a prevalence of 16.3%. In China, Iran, Saudi Arabia, and Israel, 10%, 30.3%, 41.9%, and 5%, respectively.

In Europe, greater resistances are seen in southern countries. In Germany, the studies show a prevalence of 8%. In France (very close to Spain) we can observe a prevalence of 3.3% as seen in 2013.

The data of Spain are very limited, but in 2000 a report showed that the prevalence of ESBL-producing E.coli was about 0.5% while in 2005 this number grew to 8.2%, which is 16 times greater.

Bearing in mind the lack of information in this matter in children in Spain, we tried to study the prevalence of community-onset ESBL-producing E coli urinary tract infections.

As secondary objectives, we analyzed associated risk factors and the resistance patterns in ESBL-producing E coli isolates.

2. Material and methods

We performed a retrospective observational study in a tertiary care hospital between January 1st, 2015 and December 31st,
2016. We collected data of all children ≤14 years old with community-onset *E coli* urinary tract infection who visited our emergency department in Toledo (Spain). Data for demographic characteristics, medical conditions, medication, and urinary isolates are from the patient medical record.

We considered positive isolate when >50,000 colony-forming units in the urine sample obtained by urinary catheterization (those patients without urinary continence) or spontaneous urination. We excluded those cultures separated <7 days from the previous one (we consider them as a control of the evolution of the patient), and those who were receiving antibiotic prophylaxis.

*E coli* were identified by using biochemistry procedures. Resistance detection and in vitro susceptibility were made by broth microdilution (Siemens WalkAway, West Sacramento, CA). The variables studied were age, sex, ESBL-producing, antibiotic therapy, previous hospitalization, pyelectasis, and vesicoureteral reflux. The resistances observed in ESBL-producing isolates were identified using biochemistry procedures.

SPSS v23 (SPSS Inc., Chicago, IL) was used for analysis. 

### Results

During the study period, 229 *E coli* isolates were identified from sterile samples from children in the emergency department. Twenty one (9.2%) of them were ESBL-producing *E coli*.

The median age was 17 months in all isolates, 18 months in non-ESBL-producing *E coli*, and 7 months in ESBL-producing *E coli*.

The risk factors statistical analyses and results are detailed in Table 1.

Multiple regression analyses between sex and 30 days previous hospitalization were $r=3.51$ ($P=.0001$)

The resistances observed in ESBL-producing *E coli* sample are detailed in Table 2.

Moreover, 7 (33%) of them were resistant to cephalosporins, aminoglycosides, and quinolones, and 5 (23.8%) to cephalosporins and quinolones, but not aminoglycosides. The total amount of multidrug resistant isolates among ESBL producing *E coli* was 12 (57%).

### 4. Discussion

We find that among children, the isolation of ESBL-producing *E coli* is becoming common across pediatric age groups in Spain, consistent with previous reports in adults,[13,14] and children over the world.[8,15] The spread of ESBL is plasmid-mediated, and can be transferred to other Gram-negative bacteria.[16] This fact is important to understand the easily spread of resistances in a country, and the need of national healthcare programs.

In 2015, the prevalence of ESBL-producing *E coli* among UTI caused by *E coli* was 7.1% versus 14.6% in 2016. As we can see, this rate is increasing very fast among pediatric population.

The upward trend in ESBL-producing isolates with age, is not seen in our study (median age of 7 months in ESBL-producing group vs 18 months in *E coli* isolates). This may be because the *E coli* behavior in children is different from adults.

As seen in previous studies, being male, hospitalization 30 days previous to infection,[6,15] nefrourologic pathology and vesicoureteral reflux are proposed as risk factors.

Moreover, male sex and hospitalization 30 days before infection have a combined risk of 3.51 ($P=.0001$), which should be taken into account to choose the best antibiotic regime for these children.

### Table 1

| Total | *E coli* | ESBL-producing *E coli* | N = 229 | N = 208 | N = 21 | P |
|-------|---------|-------------------------|---------|--------|--------|---|
| Sex   |         |                         |         |        |        |   |
| Male  | 80 (35%)| 66 (31.7%)              | 14 (66%)|        |        | .001|
| Female| 149 (65%)| 142 (68.2%)            | 7 (33%)|        |        |   |
| Previous hospitalization | |                       |         |        |        |   |
| 7 d   | 21 (19) | 19 (25)                 | 2 (10)  |        |        | .023|
| 15 d  | 25 (21) | 21 (26)                 | 4 (19)  |        |        | .003|
| 30 d  | 27 (22) | 22 (27)                 | 5 (24)  |        |        | .001|
| Previous antibiotic therapy | |                       |         |        |        |   |
| 7 d   | 8 (6)   | 6 (8)                   | 2 (10)  |        |        | .16 |
| 15 d  | 27 (24) | 24 (30)                 | 3 (15)  |        |        | .72 |
| 30 d  | 38 (33) | 33 (40)                 | 5 (24)  |        |        | .35 |
| Nefroulogic pathology | |                       |         |        |        |   |
| Yes   | 66 (57%)| 54 (65.1%)              | 12 (57%)|        |        | .003|
| No    | 163 (43%)| 154 (55.1%)            | 9 (43%) |        |        |   |
| Vesicoureteral reflux | |                       |         |        |        |   |
| Yes   | 31 (22) | 25 (32.5%)             | 6 (29)  |        |        | .035|
| No    | 198 (78) | 183 (67.5%)          | 15 (71) |        |        |   |

*E. coli* = *Escherichia coli*; ESBL: extended spectrum beta-lactamase.

### Table 2

| Antibiotic              | Resistance | Susceptibility | Intermediate |
|-------------------------|------------|----------------|--------------|
| Ampicillin              | 21 (100%)  | 0              | 0            |
| Amoxicillin/clavulanic acid| 13 (62%)  | 8 (38%)        | 0            |
| Piperacillin/tazobactam  | 6 (26.6%)  | 12 (57%)       | 3 (14.3%)    |
| Cefuroxime              | 18 (85.7%) | 3 (14.3%)      | 0            |
| Cefoxitin               | 2 (9.5%)   | 18 (85.7%)     | 1 (4.8%)     |
| Cefazidime              | 17 (81.9%) | 1 (4.8%)       | 3 (14.3%)    |
| Cefotaxime              | 19 (90.5%) | 2 (9.5%)       | 0            |
| Imipenem                | 0          | 21 (100%)      | 0            |
| Meropenem               | 0          | 21 (100%)      | 0            |
| Ertapenem               | 0          | 21 (100%)      | 0            |
| Gentamicin              | 8 (38%)    | 13 (62%)       | 0            |
| Tobramycin              | 9 (42.8%)  | 9 (42.8%)      | 3 (14.3%)    |
| Amikacin                | 0          | 19 (90.5%)     | 2 (9.5%)     |
| Nalidixic acid          | 15 (71.4%) | 5 (23.8%)      | 1 (4.8%)     |
| Ciprofloxacin           | 15 (71.4%) | 3 (14.3%)      | 3 (14.3%)    |
| Norfloxacin             | 17 (81.9%) | 4 (19%)        | 0            |
| Levofloxacin            | 4 (19%)    | 17 (81.9%)     | 0            |
| Trimethoprim/sulfamethoxazole | 13 (62%) | 8 (38%)        | 0            |
| Fosfomycin              | 2 (9.5%)   | 19 (90.5%)     | 0            |
| Nitrofurantoin          | 0          | 21 (100%)      | 0            |
In our sample, 57% of the ESBL-producing *E. coli* were multidrug resistant, which means that at least 5.24% of the children included have a multidrug resistant infection. They remain highly susceptible to fosfomycin, nitrofurantoin, and carbapenems.

In conclusion, the retrospective study allowed assessing the problem of ESBL-producing isolates in the outpatient settings. Some risk factors from past studies were confirmed and a combined risk is suggested. The resistant spectrum should be taken into account when choosing antibiotic regimens.

Our study has the proper limitations of an observational study. Further studies are needed to reveal the real impact of these microorganisms in national healthcare.

References

[1] European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2015. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net); 2017. Stockholm: ECDC.

[2] Kahlmeter G, Poulsen HO. Antimicrobial susceptibility of *Escherichia coli* from community-acquired urinary tract infections in Europe; the ECO SENS study revisited. Int J Antimicrob Agents 2012;39:45–51.

[3] Kahlmeter G, Menday P. Cross-resistance and associated resistance in 2478 *Escherichia coli* isolates from the Pan-European ECO.SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. J Antimicrob Chemother 2003;52:128–31.

[4] Rodrigo Gonzalo de Liria C, Méndez Hernández M, Azuara Robles M. Diagnostic-therapeutic protocols of the AEP: Pediatric Infectology. Chapter 14: urinary infection. Ed Ergon. 3 edición. 2011. Available in http://www.aeped.es/sites/default/files/documentos/itu.pdf.

[5] Thaden JT, Fowler VG, Sexton DJ, et al. Increasing incidence of extended-spectrum *β*-lactamase-producing *Escherichia coli* in community hospitals throughout the Southeastern United States. Infect Control Hosp Epidemiol 2016;37:49–54.

[6] Morfin-Otero R, Mendoza-Olazarán S, Silva-Sánchez J, et al. Characterization of Enterobacteriaceae isolates obtained from a tertiary care hospital in Mexico, which produces extended-spectrum *β*-lactamase. Microb Drug Resis 2013;19:378–83.

[7] Ho PL, Wong RC, Yip KS, et al. COMBAT study group Antimicrobial resistance in *Escherichia coli* outpatient urinary isolates from women: emerging multidrug resistance phenotypes. Diagn Microbiol Infect Dis 2007;59:439–45.

[8] Rezai MS, Salehifar E, Rafiei A, et al. Characterization of multidrug resistant extended-spectrum *β*-lactamase-producing *Escherichia coli* among uropathogens of pediatrics in North of Iran. Biomed Res Int 2015;2015:309478.

[9] Al Yousef SA, Younis S, Farrag E, et al. Clinical and laboratory profile of urinary tract infections associated with extended spectrum *β*-lactamase producing *Escherichia coli* and Klebsiella pneumoniae. Ann Clin Lab Sci 2016;46:393–400.

[10] Toubiana J, Timsit S, Ferroni A, et al. Community-onset extended-spectrum *β*-lactamase-producing Enterobacteriaceae invasive infections in children in a University Hospital in France. Medicine (Baltimore) 2016;95:e3163.

[11] Martin D, Fougnot S, Grobost F, et al. ONERBA-ville network. Prevalence of extended-spectrum *β*-lactamase producing *Escherichia coli* in community-onset urinary tract infections in France in 2013. J Infect 2016;72:201–6.

[12] Kresken M, Pfeifer Y, Hafner D, et al. Working Party ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for chemotherapy. Occurrence of multidrug resistance to oral antibiotics among *Escherichia coli* urine isolates from outpatient departments in Germany: extended-spectrum *β*-lactamases and the role of fosfomycin. Int J Antimicrob Agents 2014;44:295–300.

[13] Hernández JR, Pascual A, Cantón R, et al. Grupo de Estudio de Infección Hospitalaria. GEIH. [Extended-spectrum *β*-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in spanish hospitals (GEIH-BLEE Project 2002)]. Enferm Infecct Microbiol Clin 2003;21:77–82.

[14] García MV, Gallardo MM, Rodríguez-Ortega R, et al. Distribution of patterns of sensitivity and associated phenotypes of resistance in nosocomial and community acquired *Escherichia coli* during 2005. Rev Esp Quimioter 2008;21:157–65.

[15] Dayan N, Dabbah H, Weissman I, et al. Urinary tract infections caused by community-acquired extended-spectrum *β*-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr 2013;163:1417–21.

[16] Wragg R, Harris A, Patel M, et al. Extended spectrum *β*-lactamase (ESBL) producing bacteria urinary tract infections and complex pediatric urology. J Pediatr Surg 2017;52:284–8.